Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 18/20 | 0.51 |
| ▸ | ITGA4 | P13612 | 11/20 | 0.51 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.51 |
| ▸ | ITGA5 | P08648 | 3/20 | 0.47 |
| ▸ | ITGAV | P06756 | 6/20 | 0.42 |
| ▸ | ITGA2 | P17301 | 1/20 | 0.40 |
| ▸ | TACR1 | P25103 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3850203 | 0.87 | ITGB1 (0.50) | ITGB1ITGA4ITGB7ITGA5ITGAV | |
| SCHEMBL3848909 | 0.86 | ITGB1 (0.54) | ITGB1ITGA4ITGB7ITGA5ITGAV | |
| SCHEMBL3856670 | 0.86 | ITGB1 (0.54) | ITGB1ITGA4ITGB7ITGA5ITGAV | |
| SCHEMBL3848928 | 0.85 | ITGB1 (0.57) | ITGB1ITGA4ITGB7ITGA5 | |
| SCHEMBL3855606 | 0.85 | ITGB1 (0.54) | ITGB1ITGA4ITGB7ITGA5ITGAV | |
| SCHEMBL4413756 | 0.84 | ITGB1 (0.53) | ITGB1ITGA4ITGB7ITGA5ITGAV | |
| SCHEMBL3852610 | 0.84 | ITGA4 (0.61) | ITGB1ITGA4ITGB7ITGA5ITGAV | |
| SCHEMBL3855807 | 0.83 | ITGB1 (0.56) | ITGB1ITGA4ITGB7ITGA5ITGAV | |
| SCHEMBL3848324 | 0.83 | ITGB1 (0.57) | ITGB1ITGA4ITGB7ITGA5ITGAV | |
| SCHEMBL3851032 | 0.82 | ITGB1 (0.59) | ITGB1ITGA4ITGB7ITGA5ITGAV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6900179-B2 | Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. | 2005-05-31 | — | — | US | disclosed |
| US-20020193312-A1 | Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. | 2002-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193312-A1 | Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, L1CAM | ITGB1 64/4885ITGA4 8/4885ITGB7 296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.